Related Experiment Videos
Active specific immunotherapy of melanoma
1Centre for Biological Therapy and Melanoma Research, University of California, San Diego Cancer Centre La Jolla, USA.
British Medical Bulletin
|July 1, 1995
Summary
Active specific immunotherapy, or tumor vaccines, stimulates patients to reject tumors, showing promise in melanoma treatment. This approach offers prolonged survival with minimal toxicity, especially in early-stage disease.
Area of Science:
- Oncology
- Immunology
- Cancer Therapeutics
Background:
- Active specific immunotherapy utilizes tumor vaccines to stimulate an immune response against cancer.
- Melanoma has been a primary focus for immunotherapy, yielding encouraging outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of active specific immunotherapy in melanoma patients.
- To explore the potential of immunotherapy in both minimal residual disease and disseminated melanoma settings.
Main Methods:
- Treatment involved the administration of tumor vaccines to stimulate anti-tumor immunity.
- Patient outcomes were assessed in terms of survival and treatment-related toxicity.
Main Results:
- Encouraging results were observed in melanoma patients treated with immunotherapy.
- Prolonged survivals, extending several years, were achieved, particularly in patients with minimal residual disease post-surgery.
- The treatment demonstrated minimal toxicity.
Conclusions:
- Active specific immunotherapy is a promising approach for melanoma treatment, offering significant survival benefits.
- Future advancements in vaccine preparation, utilizing genetic and biochemical methods, are expected to enhance efficacy and introduce defined components.